API | nelotanserin

nelotanserin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Nelotanserin is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia. It was shown to be effective and well tolerated in clinical trials, but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints. Research continues on newer analogues which may potentially be more successful. ^Wikipedia

Chemistry

SMILES: COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1c3c(Br)cnn3C
InChIKey: COSPVUFTLGQDQL-UHFFFAOYSA-N
Mol. Mass: 437.24
ALogP: 4.78 Partition coefficient
ChEMBL Molecule:
nelotanserin

More Chemistry

Pharmacology

Mechanism of Action:
- 5-hydroxytryptamine receptor 2A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

apd125 | apd-125 | nelotanserin

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Hallucinations (Phase 2)

Lewy Body Disease (Phase 2)

Parkinson Disease (Phase 2)

REM Sleep Behavior Disorder (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue